中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(8): 1753-1757

Targeted therapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2021.08.003

  • Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

Research funding:

Project of Tianjin Municipal Bureau of Science and Technology (19YFZCSY00020)

  • Received Date: 2021-03-15
  • Accepted Date: 2021-04-15
  • Published Date: 2021-08-20
    Abstract
  • With the in-depth research on the molecular mechanism of hepatocellular carcinoma (HCC) in recent years, targeted therapy has achieved rapid development and made great contributions to delaying disease progression and improving prognosis. Due to the complex pathogenesis of HCC, molecular targeted therapy alone has unsatisfactory overall clinical benefits; therefore, new treatment regimens of targeted therapy in combination with other treatment modalities continue to appear in recent years and have obtained encouraging results. This article briefly summarizes the drugs used in molecular targeted therapy, the current research status of molecular targeted therapy, and the advances in its combination with other treatment modalities for HCC.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-1953. DOI: 10.1002/ijc.31937.
    [2]
    ALQAHTANI A, KHAN Z, ALLOGHBI A, et al. Hepatocellular carcinoma: Molecular mechanisms and targeted therapies[J]. Medicina (Kaunas), 2019, 55(9): 526. DOI: 10.3390/medicina55090526.
    [3]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [4]
    NORDENSTEDT H, WHITE DL, EL-SERAG HB. The changing pattern of epidemiology in hepatocellular carcinoma[J]. Dig Liver Dis, 2010, 42(Suppl 3): s206-s214. DOI: 10.1016/S1590-8658(10)60507-5.
    [5]
    LIU M, JIANG L, GUAN XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: A recent update[J]. Protein Cell, 2014, 5(9): 673-691. DOI: 10.1007/s13238-014-0065-9.
    [6]
    DIMRI M, SATYANARAYANA A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma[J]. Cancers (Basel), 2020, 12(2): 491. DOI: 10.3390/cancers12020491.
    [7]
    GONG X, QIN S. Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr, 2018, 7(6): 466-474. DOI: 10.21037/hbsn.2018.11.04.
    [8]
    LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. DOI: 10.1056/NEJMoa0708857.
    [9]
    CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34. DOI: 10.1016/S1470-2045(08)70285-7.
    [10]
    KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [11]
    MATSUKI M, HOSHI T, YAMAMOTO Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models[J]. Cancer Med, 2018, 7(6): 2641-2653. DOI: 10.1002/cam4.1517.
    [12]
    WILHELM SM, DUMAS J, ADNANE L, et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J]. Int J Cancer, 2011, 129(1): 245-255. DOI: 10.1002/ijc.25864.
    [13]
    FONDEVILA F, MÉNDEZ-BLANCO C, FERNÁNDEZ-PALANCA P, et al. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers[J]. Exp Mol Med, 2019, 51(9): 1-15. DOI: 10.1038/s12276-019-0308-1.
    [14]
    CERRITO L, PONZIANI FR, GARCOVICH M, et al. Regorafenib: A promising treatment for hepatocellular carcinoma[J]. Expert Opin Pharmacother, 2018, 19(17): 1941-1948. DOI: 10.1080/14656566.2018.1534956.
    [15]
    BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-6736(16)32453-9.
    [16]
    FINN RS, MERLE P, GRANITO A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase Ⅲ RESORCE trial[J]. J Hepatol, 2018, 69(2): 353-358. DOI: 10.1016/j.jhep.2018.04.010.
    [17]
    DEEKS ED. Cabozantinib: A review in advanced hepatocellular carcinoma[J]. Target Oncol, 2019, 14(1): 107-113. DOI: 10.1007/s11523-019-00622-y.
    [18]
    SCOTT AJ, ARCAROLI JJ, BAGBY SM, et al. Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms[J]. Mol Cancer Ther, 2018, 17(10): 2112-2122. DOI: 10.1158/1535-7163.MCT-17-0131.
    [19]
    ABOU-ALFA GK, MEYER T, CHENG AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1): 54-63. DOI: 10.1056/NEJMoa1717002.
    [20]
    LIAO W, HUANG J, HUTTON D, et al. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma[J]. Liver Int, 2019, 39(12): 2408-2416. DOI: 10.1111/liv.14257.
    [21]
    KUDO M, HATANO E, OHKAWA S, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial[J]. J Gastroenterol, 2017, 52(4): 494-503. DOI: 10.1007/s00535-016-1247-4.
    [22]
    ZHU AX, KANG YK, YEN CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296. DOI: 10.1016/S1470-2045(18)30937-9.
    [23]
    LI Q, QIN SK, GU SZ, et al. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase Ⅲ study[J]. J Clin Oncol, 2020, 38(15_suppl): 4507. DOI: 10.1200/JCO.2020.38.15_suppl.4507.
    [24]
    Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of primary liver cancer (2020 edition)[M]. Beijing: People's Medical Publishing House, 2020.

    中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020.
    [25]
    BI F, QIN SK, GU SZ, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase Ⅱ/Ⅲ trial[J]. J Clin Oncol, 38(15_suppl): 4506. DOI: 10.1200/JCO.2020.38.15_suppl.4506.
    [26]
    VENEPALLI NK, GOFF L. Targeting the HGF-cMET axis in hepatocellular carcinoma[J]. Int J Hepatol, 2013, 2013: 341636. DOI: 10.1155/2013/341636.
    [27]
    GHERARDI E, BIRCHMEIER W, BIRCHMEIER C, et al. Targeting MET in cancer: Rationale and progress[J]. Nat Rev Cancer, 2012, 12(2): 89-103. DOI: 10.1038/nrc3205.
    [28]
    BOUATTOUR M, RAYMOND E, QIN S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma[J]. Hepatology, 2018, 67(3): 1132-1149. DOI: 10.1002/hep.29496.
    [29]
    XIANG Q, CHEN W, REN M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET[J]. Clin Cancer Res, 2014, 20(11): 2959-2970. DOI: 10.1158/1078-0432.CCR-13-2620.
    [30]
    ZHAO H, LV F, LIANG G, et al. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation[J]. Oncotarget, 2016, 7(12): 13575-13586. DOI: 10.18632/oncotarget.6185.
    [31]
    RAJA A, PARK I, HAQ F, et al. FGF19-FGFR4 signaling in hepatocellular carcinoma[J]. Cells, 2019, 8(6): 536. DOI: 10.3390/cells8060536.
    [32]
    LIN BC, DESNOYERS LR. FGF19 and cancer[J]. Adv Exp Med Biol, 2012, 728: 183-194. DOI: 10.1007/978-1-4614-0887-1_12.
    [33]
    VILLANUEVA A, CHIANG DY, NEWELL P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma[J]. Gastroenterology, 2008, 135(6): 1972-1983. DOI: 10.1053/j.gastro.2008.08.008.
    [34]
    HUYNH H, CHOW KH, SOO KC, et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma[J]. J Cell Mol Med, 2009, 13(7): 1371-1380. DOI: 10.1111/j.1582-4934.2008.00364.x.
    [35]
    SHIAH HS, CHEN CY, DAI CY, et al. Randomised clinical trial: Comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2013, 37(1): 62-73. DOI: 10.1111/apt.12132.
    [36]
    FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
    [37]
    FINN RS, IKEDA M, ZHU AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/JCO.20.00808.
    [38]
    YAU T, ZAGONEL V, SANTORO A, et al. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040[J]. J Clin Oncol, 38(4_suppl): 478. DOI: 10.1200/JCO.2020.38.4_suppl.478.
    [39]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [40]
    KUDO M, UESHIMA K, IKEDA M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69(8): 1492-1501. DOI: 10.1136/gutjnl-2019-318934.
    [41]
    CHEN JH, LU L, WEN TF, et al. Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE): Interim results from a muticenter prospective cohort study[J]. J Clin Oncol, 2020, 38(15_Suppl): 4580.
    [42]
    HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
    [43]
    FENG X, XU R, DU X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: A multicenter retrospective cohort study[J]. Am J Gastroenterol, 2014, 109(12): 1891-1899. DOI: 10.1038/ajg.2014.343.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (934) PDF downloads(205) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return